12:00 AM
Jan 02, 2012
 |  BC Week In Review  |  Clinical News  |  Clinical Results

Beraprost-MR: Phase II data

United Therapeutics said a Phase II trial in patients with PAH showed that beraprost-MR missed the primary and secondary endpoints. Details were not disclosed. The company has suspended plans to start a...

Read the full 136 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >